Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hoepner

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Bioengineering (Basel, Switzerland)|August 29, 2024
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric CohortMartina Greselin, Po-Jui Lu, Lester Melie-Garcia, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Brain : a Journal of Neurology|November 14, 2025
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosisAleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 19, 2025
Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple SclerosisXinjie Chen, Po-Jui Lu, Mario Ocampo-Pineda, et al.
Annals of Neurology|October 16, 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple SclerosisPascal Benkert, Aleksandra Maleska Maceski, Sabine Schaedelin, et al.
JAMA Neurology|June 2, 2025
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated SyndromeNicolás Fissolo, Sabine Schaedelin, Luisa M Villar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 12, 2025
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysisAhmed Abdelhak, Franziska Bachhuber, Kiarra Ning, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Bioengineering (Basel, Switzerland)|August 29, 2024
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric CohortMartina Greselin, Po-Jui Lu, Lester Melie-Garcia, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Brain : a Journal of Neurology|November 14, 2025
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosisAleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 19, 2025
Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple SclerosisXinjie Chen, Po-Jui Lu, Mario Ocampo-Pineda, et al.
Annals of Neurology|October 16, 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple SclerosisPascal Benkert, Aleksandra Maleska Maceski, Sabine Schaedelin, et al.
JAMA Neurology|June 2, 2025
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated SyndromeNicolás Fissolo, Sabine Schaedelin, Luisa M Villar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 12, 2025
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysisAhmed Abdelhak, Franziska Bachhuber, Kiarra Ning, et al.
Pageof 13